Corporate | 7 December 2010 07:30
4SC AG / Key word(s): Miscellaneous
4SC AG: U.S. Patent Granted for 4SC's Oral HDAC Inhibitor Resminostat
(4SC-201)
07.12.2010 / 07:30
Planegg-Martinsried, Germany, 7 December 2010 - 4SC AG (Frankfurt, Prime
Standard: VSC), a drug discovery and development company focused on
autoimmune and cancer indications, today announced that the U.S. Patent and
Trademark Office has granted patent 7842820 for resminostat (4SC-201), an
oral histone deacetylase (HDAC) inhibitor. This molecule is currently being
developed in two Phase II trials in hepatocellular carcinoma and Hodgkin's
lymphoma.
The patent, entitled 'novel sulfonylpyrroles', covers the composition of
matter and pharmaceutical compositions of a novel group of compounds,
including resminostat, which inhibit HDACs. Resminostat is an oral HDAC
inhibitor that targets a spectrum of HDAC isoenzymes. HDAC inhibitors
modify the DNA arrangement of tumor cells to cause their differentiation
and programmed cell death (apoptosis). This mechanism of action is
considered to offer the particular potential to halt tumor progression and
induce tumor regression in various cancers.
Dr Bernd Hentsch, Chief Development Officer at 4SC, commented: 'We are
pleased to have received this patent for our lead oncology compound
resminostat, which is the first of two HDAC inhibitors in our pipeline. The
current Phase II trials in hepatocellular cancer and Hodgkin's lymphoma are
progressing well and we look forward to commencing a Phase I/II trial in
K-ras-mutant colorectal cancer patients later this year. This patent
underpins the commercial potential of resminostat, which we are broadly
assessing through the selection of three cancer indications with different
treatment paradigms, evaluating resminostat in monotherapy trials as well
as in combination treatment approaches.'
About Resminostat (4SC-201)
Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor.
HDAC inhibitors modify the DNA structure of tumour cells to cause their
differentiation and programmed cell death (apoptosis) and are therefore
considered to offer a mechanism of action that has the particular potential
to halt tumour progression and induce tumour regression. Resminostat is
currently in a Phase II study as a second line treatment for advanced
hepatocellular carcinoma and as a third-line treatment in Hodgkin's
lymphoma. In a completed Phase I trial in patients with various different
cancer types, stable disease was achieved in over 50% of the patients,
whilst the treatment was well tolerated and showed a positive,
differentiating pharmacological profile to other drugs in this class.
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in Phase II development in rheumatoid
arthritis and inflammatory bowel disease (IBD), for which positive results
from a Phase IIa study were recently reported. The company's lead oncology
compound, resminostat (4SC-201), a pan histone deacetylase (HDAC)
inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's
lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205 are in Phase
I studies. 4SC develops drug candidates until proof-of-concept in order to
generate value creating partnerships with the pharmaceutical industry in
return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please contact
4SC AG
Yvonne Alexander
Investor & Public Relations
Tel.: +49 (0) 89 70 07 63 - 66
yvonne.alexander@4sc.com
MC Services
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 - 30
raimund.gabriel@mc-services.eu
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
crubin@troutgroup.com
End of Corporate News
07.12.2010 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
105597 07.12.2010